Table 3.
Association between clinical and serologic variables of PLWHIV and neutralising antibody activity (ND50) since the second dose of mRNA-1273 vaccine.
| Variable | Subjects (n) | Neutralising antibody activity (ND50) | p-value |
|---|---|---|---|
| Sex* | 0·50 | ||
| Male | 60 | 1513 (789-3531) | |
| Female | 11 | 1225 (700-2516) | |
| Age (years)° | 0·48 | ||
| <35 | 17 | 1608 (924-2897) | |
| 35-50 | 22 | 1752 (719-4291) | |
| 50-60 | 22 | 1041 (741-1609) | |
| >60 | 10 | 2492 (877-5228) | |
| Antiretroviral therapy° | 0·36 | ||
| NRTI | 65 | 1567 (769-3531) | |
| InSTI | 55 | 1419 (771-3437) | |
| NNRTI | 8 | 525 (130-5158) | |
| PI | 10 | 1154 (363-3335) | |
| Plasma HIV viral load§ | 71 | ||
| (slope; 95% CI) | (0·81; 0·38,1·71) | 0·57 | |
| CD4+ T cell count per µL° | 0·03 | ||
| <350 per µL | 6 | 1314 (606-2477) | |
| 350-500 per µL | 7 | 3329 (1905-10508) | |
| >500 per µL | 58 | 1227 (761-3032) | |
| CD4+ T cell count percentage§ | 71 | ||
| (slope; 95% CI) | (0·98; 0·96,1·00) | 0·11 | |
| CD4+ T/CD8 ratio >=1* | 0·94 | ||
| No | 39 | 1828 (807-5142) | |
| Yes | 32 | 1119 (756-1903) | |
| CD4+ T/CD8 ratio >=0·4* | 0·55 | ||
| No | 14 | 1588 (935-3561) | |
| Yes | 57 | 1250 (771-3437) | |
| Optimal immunologic response†,* | 0·07 | ||
| No | 42 | 1824 (826-5142) | |
| Yes | 29 | 1159 (745-1827) | |
| HCV-Ab* | 0·88 | ||
| Negative | 59 | 1567 (771-3437) | |
| Positive | 5 | 2516 (675-4291) | |
| HBsAg* | 0·32 | ||
| Negative | 62 | 1598 (771-3501) | |
| Positive | 2 | 861 (719-1004) | |
| Years since diagnosis§ | 71 | ||
| (slope; 95% CI) | (0·98; 0·96,1·01) | 0·23 | |
| (CD4+ T cell count per µL)[2] at nadir§ | 71 | ||
| (slope; 95% CI) | (0·99; 0·86,1·14) | 0·89 | |
| Plasma HIV viral load at zenith§ | 71 | ||
| (slope; 95% CI) | (1·09; 0·72,1·64) | 0·68 | |
| AIDS diagnosis* | 0·83 | ||
| No | 31 | 1567 (864-3437) | |
| Yes | 19 | 1393 (674-3501) | |
| CMV IgG* | 0·84 | ||
| Negative | 5 | 935 (741-2137) | |
| Positive | 38 | 1406 (719-3157) | |
| Anti-N* | <0·001 | ||
| Negative | 9 | 1192 (742-2421) | |
| Positive | 61 | 10888 (2478-14416) |
CI, confidence interval; NRTIs, nucleoside reverse transcriptase inhibitors; InSTIs, integrase strand transfer inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen; CMV, cytomegalovirus; anti-N, anti-nucleocapsid protein.
†
Optimal immunologic response was defined as: CD4+ T/CD8 ratio≥1 plus CD4+ T≥500cells/µL plus CD4+ T%≥30%. Statistics calculated using
⁎
Mann–Whitney U test,
°
Kruskal-Wallis test or
§
Spearman's rank correlation coefficients.